PCVX vs SNY

Sanofi (SNY) offers the better valuation at 18.

1x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Vaxcyte, Inc. (PCVX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Vaxcyte, Inc.

(PCVX) delivered a total return of +191. 8%, compared to +2. 5% for Sanofi (SNY). Over 10 years, the gap is even starker: PCVX returned +96. 9% versus SNY's +57. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sanofi (SNY) is the lower-risk stock at 0.

51β versus Vaxcyte, Inc. 's 1. 07β — meaning PCVX is approximately 109% more volatile than SNY relative to the S&P 500. On balance sheet safety, Vaxcyte, Inc. (PCVX) carries a lower debt/equity ratio of 9% versus 30% for Sanofi — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Sanofi grew EPS -7.

3% year-over-year, compared to -48. 2% for Vaxcyte, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sanofi (SNY) is the more profitable company, earning 16.

7% net margin versus 0. 0% for Vaxcyte, Inc. — meaning it keeps 16. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SNY leads at 13. 6% versus 0. 0% for PCVX. At the gross margin level — before operating expenses — SNY leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PCVX: 61.

2% to $83. 00.

In this comparison, SNY (5.

1% yield) pays a dividend. PCVX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Sanofi (SNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

51), 5. 1% yield). Both have compounded well over 10 years (SNY: +57. 1%, PCVX: +96. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PCVX is a small-cap quality compounder stock; SNY is a mid-cap income-oriented stock. SNY pays a dividend while PCVX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.